near-term catalyst consider head
hc
weve consist highlight bullish outlook stori
head compani multipl driver out-performance
includ acceler top-lin growth multipl new product launch
catalyst new ceo stori even look near-term howev
believ worth highlight number import event catalyst keep
first month expect near-term item key
focu compani upcom presenc morgan healthcar
confer walk put take item
start updat forecast account extra sell
week add
exact nuanc saw year
headwind also expect repres similar tailwind quarter
full year importantli back tailwind
denomin follow year get apples-to-appl organ
growth-rat quarters/year howev benefit ep
move catalyst upcom nan confer bigger
focu follow stimgen acquisit highlight recent
note see data sgx-scs-rct compar usag
recent acquir stimgen dtm tradit waveform also
see compani launch next-gener intelli devic someth could
help compani revit growth meaning deceler
saw could also see increas attent place upcom
insterstim micro launch expect earli
much-await micra av pacemak also launch early-
start europ us follow closer begin
overal pipelin micra av repres one vet
product investor standpoint still like opportun
under-model street initi leadless pacemak offer
micra vr success address overal
pacemak market help acceler compani growth area
growth come share-tak hold
unit volum share revenu share global single-chamb
pacemak market pre-micra price uplift micra vr
command premium legaci devic micra av add sensor
detect heart atrium contract expand product capabl
addit pacemak market expect similar progress
saw vr take share benefit
price premium convert user legaci competit product
sourc style exposur morgan quantit deriv strategi tabl compani data morgan estim
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
summari invest thesi valuat
past year weve seen signific turnaround
perform manag return
consist exceed expect importantli
materi improv gener
stick point mani investor next month
believ medtron grow least plu see
number underappreci data present
transform new product launch appear
fulli appreci street conserv leav
potenti catalyst see come upsid vs
forecast manag set appropri
conserv bar long-rang top-lin earn
progress june analyst day see meaning
upsid street estim year ahead potenti
multipl expans sustain execut
dec price target share
base price-to-earnings multipl slight discount
large-cap med-tech peer set appli calendar ep
million
cash-flow oper
margin growth
sourc perform driver bloomberg morgan quantit deriv strategi tabl compani data morgan estim
diabet busi well get advanc hybrid close loop pivot data
advanc technolog treatment diabet aatd meet madrid
februari follow eu us launch shortli becom first
market bud hybrid-clos loop field upon approv septemb
second-gen system track approv launch
improv experi includ auto-correct bolus
around mealtim simplifi therapi patient expect time rang
tir vs target mg/dl glucos level vs
mg/dl expect averag time closed-loop mode vs
today easi comp due delay revenu recognit
uptick new pump sale expect strong underli
see data symplic off-m pivot trial
symplic spyral renal denerv product march symplic spyral
devic treat uncontrol hypertens altern drug
remind acquir symplic renal denerv platform
purchas mountain view ca-bas ardian novemb follow year
devic market develop therapi suffer major setback form
fail us pivot trial renal denerv arm fail meet
primari efficaci endpoint reduct offic systol bp compar control
arm build support data recent posit off-m
data could help mount comeback repres potenti
opportun entir left number
atrial fibril space present data diamond-af ii
studi diamondtemp product hr may januari
bought epix privat diamondtemp ablat system
radiofrequ system use heat scar treat target heart tissu
cold treatment fast-grow atrial fibril market specif
rf solut make competit treat paroxysm af patient
repres half overal market follow data read-out hr
would expect fda approv within month like europ
product alreadi approv expect full commerci launch back half
invest thesi valuat risk
past year weve seen signific turnaround perform
manag deliv four consecut beat-and-rais quarter
top- bottom-lin out-performance return consist exceed
expect importantli materi improv gener
stick point mani investor next month believ
grow least plu see number underappreci data
present transform new product launch appear fulli
appreci street conserv leav potenti catalyst
see come upsid vs forecast manag set appropri
conserv bar long-rang top-lin earn progress june
analyst day see meaning upsid street estim year ahead
potenti multipl expans sustain execut
dec price target share base price-to-earnings multipl
slight discount large-cap med-tech peer set appli calendar
ep estim see appropri given compani in-lin outlook
long-term off-set modest headwind near-term
risk rate price
downsid risk includ slower growth and/or increas competit core end
market slower-than-anticip adopt new technolog poor
deploy capit lack gener
medtron plc summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end apr o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect research analyst person view subject secur issuer
part research analyst compens directli indirectli relat specif recommend
view express research analyst report korea-bas research analyst list front cover applic
also certifi per kofia requir analysi made good faith view reflect opinion
without undu influenc intervent
author name within report research analyst unless otherwis specifi europ sector specialist may shown
report contact author report part research depart
